secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001636282-25-000063
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.
- Advisory vote on executive compensation approved: 42.9M for, 3.1M against, 0.1M abstain, 3.1M broker non-votes.
- Ratified KPMG LLP as independent auditor for FY2025: 49.2M for, 57k against, 9k abstain, no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/0001636282-25-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000063/syre-20250529.htm
  HTML page:      https://secwatch.observer/filing/0001636282-25-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer